Epizyme scores $4M in ongoing GSK alliance

Epizyme took in a $4 million in milestone payments from partner GlaxoSmithKline ($GSK) after achieving some pre-clinical goals in the epigenetic alliance announced in January 2010. With up to $630 million in total milestones at stake for Epizyme in the deal, the Cambridge, MA-based developer (a 2011 Fierce 15 company) is working with GSK on small molecules that home in on epigenetic enzymes called histone methyltransferases to combat cancer and other illnesses. Release

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.